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INTRODUCTION

The purpose of this project is to examine the costs associated
with the FDA approval process and to determine if such costs meet
the criteria of capitalized research and development costs.

under

normal circumstances all research and development cost are treated
as expenses when incurred.

There is an exception to this rule

which

capitalized if

allows costs to

requirements.

be

they meet

certain

I will explore this area and these requirements to

determine if FDA approval costs can be capitalized.
The reason for examining this topic is because often companies
are frustrated

by expensing

all the costs incurred

through

research

and development along with the millions of dollars spent each year
on

FDA

They would

approval.

prefer

to practice

the matching

principle which states that expenses should be matched with
revenues.
avoiding
incur

This
such

large

revenues
This

would

make

expenses

to offset

topic

their

has never

company

on the

look more

income

their

expenses.

been

addressed

profitable

statements

until

in any articles

by
they

or books

I find it interesting to examine a topic for

as far as I know.

It's a topic

which there is no one correct answer at this time.

that many people probably don't consider unless they are in a
specific

The
sections.

industry

that

remainder
I will

requires

of

this

begin

related to this topic.
explanations

of what

FDA approval.

paper

by describing

will

contain

the

the background

following

information

In this section I will give detailed

FDA costs

are, what
1

the accounting

rules

officially

state,

and why this is an accounting

issue.

I will also

describe articles that relate to these topics along with company
examples from their financial statements.
The

next

section

will

examine

the

different

alternati ves

regarding FDA costs.

I will consider whether the reporting options

are

with

in

accordance

Board(FASB)'s

the

Financial

pronouncements.

professionals'

I

Accounting

will

also

Standards

state

other

opinions and agree with or refute them.

The last section will consist of recommendations made by
myself and other professionals.

I will also explain the effect the

recommendations will have on companies who incur FDA approval
costs.
BACKGROUND
RESEARCH

AND DEVELOPMENT

In October
(FASB) issued
"Accounting

1974,

COSTS

the Financial

a Statement
for

of Financial

Research

and

Accounting

Standards

Accounting

Standards

Development

Costs."

This

Board
No.2,

is the

accounting rule that still exists presently which states that "all
research

and development

the expected

value

costs

must

of R&D is zero."

be expensed
(Bierman

48)

when

incurred

and

The exception

to

this rule is when definite future benefits can be defined, then and

only then can they capitalize research and development.

This

accounting treatment caused an uproar among many professionals
along with many companies

and

development

development

every

who spend millions

year.

of dollars

on research

Prior treatment of research and

costs allowed more capitalization

2

along with giving

value to research and development.

The FASB 's definition of research and development is as
follows:

Research

is planned

search

or critical

investigation

aimed

at

discovery of new knowledge with the hope that such knowledge will
be useful in developing a new product or service, a new process or
technique,
existing

or in bringing

product

Development

is

about a significant

or process. (Keiso

the

translation

& Weygandt

of

improvement

to an

607)

research

findings

or

other

knowledge into a plan or design for a new product or process or for
a significant improvement to an existing product or process whether

intended for sale or use.(Kieso & Weygandt

607)

For specific

examples of what costs can be included in research and development
costs

and which

ACCOUNTING

costs

be excluded,

see Appendix

A.

ISSUE

After making
research

must

and development

considerations

decision regarding the expensing of

the 1974

supporting

costs, the FASB offered
their decision:

"1) Uncertainty

benefits;

2) Lack of causal

benefits;

3) R&D does not meet the accounting

4) Matching
information

One
development

of revenues

relationship

and expenses;

for investment

consideration

and credit

in

favor

costs is the uncertainty

the following

between

of future

expenditures

and

concept

of an asset;

and 5) Relevance

of resulting

decisions. "(Bierman

of

expensing

48)

research

of future benefits.

and

This view

Many companies begin research

is fairly easy to understand.

projects without knowing whether they are going to succeed or fail
3

It is

because there is always a high degree of risk involved.

difficult to determine what the project will be worth several years
in the future, if it will be worth anything at all.

There is a

concept of uncertainty surrounding research and development costs.
It's just the nature of this area.

On the other hand, the idea of

management planning should be considered because management

does

not want

Most

to invest

companies
research

apply

in a project

many

hours

and development

investment

along with weighing

Therefore,

involved.

to

they think

management

will

fail.

decisions

involving

the costs and benefits

engages

in

research

and

development with the expectation that future benefits will result.
Many argue that the future benefits

should be recorded

as an asset.

The second factor cited by the FASB is the lack of causal
relation

between

expenditures

and benefits.

In this case the board

implies that there is no relationship between the expenditures for
research and development and the subsequent benefits received from
research and development.

The FASB studies found this case to be

true,

studies,

but

theories

other

such as economics,

performed.
business

several

It's been
world

have proven

concluded

does produce

along with

discipline

false many economic

that considerable

benefits

other

to the firm.

research

studies
in the

"Expenditures

on

R&D to develop new products or improve old ones are likely to be
less correlated

with market

into new markets or

returns

than expenditures

for expansion

expanding market capacity."(Bierman 52)

Basically, it depends on which view is taken when looking at the
relationship.

4

Third, the FASB believes that research and development costs
do not meet the definition of an asset.

The FASB defines an asset

as probable future economic benefits obtained or controlled by a

particular entity as a result of past transactions or events
(Bierman
meet

53).

They do not believe

the definition

costs

"future

objectively
against

of an asset

economic

measured."

research

because

benefits
(Bierman

research

cannot

costs

and development

be

identified

and

This is also the reason

53)

If it's

capitalization.

and development

not

an

asset,

it

cannot

be

capitalized.
Fourth,

the issue is the matching

FASB uses the matching
(Bierman

principle

of expense

and revenue.

The

"in favor of expensing

R&D."

Bierman and Duke's opinion of this argument is

53)

similar to everyone else's.

They argue that "the only reason R&D

expenditures are made is to benefit future time periods by
generating

new

revenues

in those

time

periods."

They

also

argue

that "the expensing of R&D consistent with matching is a conclusion
that is difficult
of

accounting

standards

This

illustrates

both

sides

decisions.

purpose

They

that

matching

the matching

a basic principle

principle."

principle

(Bierman

53)

can be utilized

for

the last factor the FASB cited as support is the

of

resulting
(

Bierman

in allocating

also

the

-

and goes against

of the argument.

Finally,
relevance

to comprehend

state

information

for

investment

53)

The FASB

suggests

these

expenses

throughout

that

"the

capitalization
5

and

credit

that there
several

of

is no

periods.

research

and

development costs is not useful in assessment of the earnings
potential

of the enterprise."

(Bierman 53)

The FASB translates

this to mean that capitalizing research and development costs would
not

make

a

substantial

financial statements.

difference

to

investors

who

use

the

Dukes performed tests relating to the amount

of reliance placed on the financial statements regarding research
and

development

between
future

research
return

development

He found that there were relationships

costs.

and development

of a security.

costs

and the prediction

His opinion

cost are capitalized,

of the

is that when research

and

it helps an investor predict a

return because the investor is aware of possible new discoveries

that would increase the value of a company.
development
largely

affect

amount.

the financial

Tests

capitalized,
than

costs can be a major

FASB's
opposed

the

costs
above

decision

rule

research

accurately
were

factors

to

of a company

and can

and the earnings

per share

and development

costs

reflects

the

earnings

per

are

share

expensed.
are presented

expense

research

as justification

and

development

of the

costs

as

The opinion of Bierman and Dukes is

to capitalization.

that this

statements

that when

it more

if these
All

show

expense

Research and

is not based

on sound

accounting

theory

but rather

is intended to avoid criticism and conflict when the benefit from
research and development
outlay. (Bierman 54).
since determining

is determined

Overall, the problem is difficult to solve

the future benefits

can be very difficult,

to be less than the cost

from research

if not impossible.
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and development

The FASB attempts

to

be

conservative yet, at the same time, is hurting many companies who
incur large amounts of expense.
ARTICLES
There have been numerous written opinions regarding the topic
of expensing research and developments costs.

The bulk of opinions

oppose this accounting rule mainly because it violates the matching
principle.

In Roula Khalaf's article "Fuzzy Accounting"
"the debate

whether

in accounting."(96)
accounting

more

or defer costs is one of the biggest

He agrees that the main problem with this

rule is that the matching

also thinks
defined.

to expense

that

the rules

The translation

structure

he states that

principle

regarding

capitalization

of this opinion

surrounding

is not followed.

are not well-

is that there

capitalization

rules

He

needs to be

instead

of

only

stating that those costs which provide economic future benefits can
be capitalized.

If the rules are more clearly defined, there may

be less opposition

to the expensing of research and development

costs.
This point of view is also shared by Maurice S. Newman in his
article "Accounting for Research and Development."

His opinion is

that the current accounting rule regarding research and development
costs violates the matching principle.
been

influenced

Service(IRS).
"simple

too much

by the Congress

and the Internal

Revenue

He also understands that it is impossible to find a

formula"

wide variation

He feels that this rule has

for research

and development

in the amount of research
7

because

there

and development

is a

costs

incurred

in different

industries.

For example,

the pharmaceutical

industry spends the most money on research and development
exceeding billions of dollars.
should reconsider
expenses.

His conclusion

its pronouncement

often

is that the FASB

on research

and development

This is the conclusion shared by many individuals both

inside and outside the accounting field.
Lynn

W. Ellis

slightly

In

and Robert

different,

their

article

Today's

Technology"

expenses

should

and development

opinion

G. McDonald

about

"Reforming
they

usually

Management

state

be considered

research

that

express

and development

Accounting

research

up a major

Support

development

cost.

portion

yet

costs.

to

and

part of the product

makes

a similar,

Research

of the

product

cost. If research and development is not included in product cost,
it provides
costs

an inaccurate

estimate of what the product

to manufacture.

A good point made by Ellis and McDonald
enhancing

activities

manufacturing
rather

idea

actually

development,

than

as

in the

area of research

and development

R&D,

are treated

as investments

in the

"research

such

is that

market

development

as expenses

future."(31)

and

to be minimized
This

and development

that drives

"growth-

is central

expenses.

the economy."

It's

(Newman

6)

If

research and development is not encouraged no new products will be
developed,

economy

the

and

rate

of technology

companies

consumer's

well-being

especially

in

the

will
to

change

suffer.

encourage

pharmaceutical
8

will

decrease,

It is also
research

industry.

and

and

essential

the

to

development,

Having

companies

expense

to

all research

incur

research

and development

and

costs does not encourage

development

costs.

This

them

treatment

of

research and development cost could prevent the discovery of vital
drugs/products that may save people from serious diseases or other
problems.
The Ellis and McDonald

article

also mentioned

the violation

of

the matching principle and how there is now less disclosure in
research
others

and
that

development
feel

endeavors.

research

and

They share the opinion of

development

costs

need

a detailed

analysis keeping in mind those businesses who incur excessive
research

and development

costs.

A final viewpoint is that of David E. Nix and Paul E. Nix in

their article "It's Time to Change the Financial Accounting
Treatment of R&D Expenditures."
opinions

of

accounting

others

treatment

developed.
principle

the

stated

above.

is obsolete

They concur
is violated

Once again they follow the

and

They

that

with the others'

new

opinion

by the FASB ignoring

believe
methods

that

the

should

be

that the matching

sound accounting

theory.

They go on to state that the United States is at a competitive
disadvantage

since many
allowed

because

other

to defer

of their treatment

countries,
their

The difference

of research

such as Australia

research

and development

and development

and Canada,

are

expenses.

in this article from all the others is that

they offer an al ternati ve approach.

This approach

involves

placing

all research and development expenses incurred into a contra
stockholder's

equity

account

instead

9

of expensing

the costs.

This

approach

looks more at the long-term

expenses

because

research

development projects almost always last more than one year.

and

This

approach will be discussed more thoroughly later.
All the articles cited basically express the same view point
that

the

accounting

area

of conflict

rules

need

surrounding

to be changed.

research

This

is the main

and development

costs.

It

seems as if the majority of people do not side with the FASB on
this

issue.
My conclusions

of these articles

leads me to

believe that there are some definite misunderstandings

between the

and

FASB

from the analysis

accountants

in general.

The main

The matching

matching

principle.

expense

recognition

that

principle

is tied to revenue

area

is with

is defined

the

as the

recognition.

The

expenses should be matched with revenue whenever it is reasonable
and practical
expense

to do so.

recognition

that are being
benefits.

pattern

received

Also,

It also goes on to say that
involves

as well as the costs

some costs

period

simply because

(Kieso

& Weygandt

assumptions

are charged

no confection

associated

to expense

with revenue

clause

their

research

the FASB'

no connection

of

with those

in the current

can be determined.

607-8)

about no connection

supports

type

about the benefits

This definition clearly explains why the FASB
advocate

this

s opinion

and development
between

costs

is able to

treatment.

the costs and benefits

and the opposition's

opinion.

The

partially
There is

currently but in the long-term outlook there is a

connection.

10

The other clause that the FASB seems to use to support its
opinion are the words "reasonable and practical."

The FASB does

not support the view that capitalizing research and development is
reasonable

and

Their

practice.

opinion

is that

capitalizing

research and development costs causes more harm then good and its
only fair to have one standard way of handling these costs.
FDA APPROVAL COSTS
The next area of investigation
costs.

This

FDA costs,
research
costs

includes

is the definition

describing

determining

if these

and development

the purpose
costs

expenses,

meet

of the FDA,

the qualifications

and finally

analyzing

First we must look at the FDA's purpose.

for

the

safety

devices,

3)

for

if these

The Food & Drug

is a "scientific regulatory Agency responsible

of the

biologics,

defining

or expensed.

can be capitalized

Administration(FDA)

of FDA approval

Nation's

foods,

and electronic

cosmetics,

radiological

drugs,

products.

medical

" (Campbell

The federal government controls this Agency whose main purpose

is for public interest, that being safety and welfare.

"monitors the
assurances

industry and
that

possible

responsibility"

(Campbell

make

sure their

that

the

FDA

products

is not

provides the
the

industry

3), the industry's
are safe.

responsible

for

consumer the
is

meeting

responsibility

It is important
creating

The FDA

safe

best
its

being to

to understand
products,

but

only to test and monitor products to be confident that they are
harmless.
obtain

For many of these products it is required that they

FDA approval

before

the products

11

can be used

legally.

Average
Step

·

Preclinical testing
IND- approval
IND phase"
(Healthy volunteers),
IND phase II
(Hundreds of patient
volunteers)
IND phase III ,
(Thousands of patient
volunteers)

a Investigational

Lois

>

TIme laved,
months

15
1
6

3

34

20

4
6

4
24

o
o

18
36

8
30

FDA approval Process
TOTAL TIME

After reform

18
1
6

NDAb preparation time

(Ember,

review time, months

Current

117
66
51
(9.75 years) (5.5 years) (4.25 years)

i

New Drug. b New Drug Application.

C&EN November

25, 1991

page

4)

Each of the phases contain numerous procedures which all
require

a large amount of time and capital.

recent

push

to

drugs/products.

speed

up

the

approval

There has been a

process

for

new

Unfortunately, along with the speedy process comes

an increase in costs.

The cost of getting a new drug/product

to

the market can range from at least $150 million to several billion
dollars depending on the type of research findings needed and the
risks

involved.
The procedures

for each step of the FDA approval

process

are

as follows(as related to drug approvals):
--Preclinical
drug/products's
The worthiness

composition
of human

--IND Approval:
clinical

trials.

the company
subject,

This

Testing:

must

step

includes

analyzing

the

and the first stages of animal testing.

testing

must

be determined.

The new drug is preliminary approved for human
In order

show:

2)the adequacy

to get approval

1)the protection
of animal

studies

13

for clinical

testing,

of the human

research

already

completed,

3)the

scientific

merits

investigator.
-- IND

of the research

(Lucas

Phase

pharmacological

of the

80)

This

I:

plan, 4)the qualifications

phase

includes

acti vi ty of a drug.

profiling

the

These procedures

safety

and

are performed

on a small number of healthy volunteers(non-patients).

This stage

determines what constitutes a safe dosage, how long the effects of
the drug

last, and the way the drug is absorbed,

metabolized, and excreted.

distributed,

The situations in this phase are highly

controlled.

--IND Phase II:

This stage begins the efficacy tests on patients,

which are "tests providing that a drug is ineffective as it is
purported to be, without harmful or disagreeable side effects,
safety being stressed." (Grabowski 22) These test are conducted on
volunteer

patients,

approximately

between

200-300

patients.

Animal

and human studies for safety are performed coincidently.

--IND

Phase III:

This stage is usually the most extensive of all

The goal in this stage is to confirm the efficacy

the trials.

results from Phase II in patients afflicted with the specific
disease.

Further,

they

--NDA Preparation Time:
from the pre-clinical
about the chemical
formulation
thousands

identify

effects.

and clinical studies along with information

and manufacturing

scientific
details.

rationale

and purpose,

This application

and

is usually

long.

--FDA Approval

Process:

analysis

all

from

adverse

This step includes gathering all the data

structure,

of pages

low-incidence

the

This step includes a final review and
information
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included

in

the

New

Drug

Application(NDA).

It

approval/disapproval

is

at

this

is given.

The

stage

FDA

uses

that

the

a team

final

approach

to

review the application.
(The above information
As mentioned
the

time

needed

drugs which

adapted

above

there

to approve

from C&EN February
has been

new

a move

25, 1991 page 30)
towards

drugs/products,

especially

are used to treat life-threatening

life-threatening

illnesses,

the FDA will

decreasing
those

illnesses.

For

allow the drug to be used

for treatment as long as it is in the marketing approval stage.

In

conjunction with this situation to the decrease in approval time is
the adoption
to various
adoption

stages

enough

they

physicians,

and

process
The

new

already

is that

to do with

done."(Hanson

receiving,

User fees are additional

in the FDA approval

of this bill

no longer
be

of user fees.

6)

"traditional

reasonable

will

be

able

to

administrative

will

somewhat

help

to reduce

overbearing

on

for the

of funding

are

speed the job that needs

additional
This means

there
the

to

funds the FDA will be

hire

staff.

because

The reason

sources

With the additional

time will be reduced
staff

process.

fees added

scientists,
the approval

are more professionals.

current

and prepare

workload

for the

which

is

future which

predicts an increase in the number of product applications.
As of the end of 1992, the user fees were apportioned
follows:

each

1) $150,000

drug

company

company

for each new drug application,

annually,

has on the market.

and

These

3) $5,000
amounts

2) $50,000

as
for

for each product

are to be phased

a

in over

a five-year period beginning in 1993 and will bring in revenues to
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the FDA totaling approximately

$75 million per year. (Adapted from

Hanson 6-7)

This may pose a problem for the smaller companies who

are

to

unable

performing

afford

costly

such

high

costs

research methods.

when

they

are

already

The federal government is

looking at allowing smaller companies to defer these fees up to one
year after gaining approval which will allow for the companies to
recognize

some income.

FDA COSTS

AS RESEARCH

AND DEVELOPMENT

The next area regarding FDA approval costs is whether they are
considered
the

research

definition

definition,

of

and

and development
research

looking

and

at the

costs.

First we must

development.
list

of what

According
constitutes

refer
to

to

this

research

and development activities, it is easy to determine that the seven
FDA approval stages are considered research and development.

The

definition of research says that it is an investigation that hopes
to

discover

Development

useful

knowledge

is the translation

for a new product

intended

costs accomplish.

to

bring

of research

for use.

about

an

findings

These definitions

improvement.

into knowledge
are what FDA

FDA approval seeks to gain new knowledge about

a product that is being developed and make sure that the product is

safe for the market.

There is much research involved in FDA

approval as explained above.
can be assumed
development

that

FDA costs

Therefore,

from the definitions

are considered

part of research

it
and

costs.

The activities I am referring to that relate to research and
development are "1) testing in search for or evaluation of product
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or process alternatives, 2) laboratory research aimed at discovery
of new knowledge,

and 3) conceptual

formulation

possible product or process alternatives."(Kieso
608)

All

these

research

and

development

and design
& Weygandt

activities

of

607-

are what

is

performed during the stages of FDA approval, so therefore the costs
from these stages

are classified

as research

and development

costs.

The second set of costs to analyze are the newly-proposed user

fees.

These fees are administrative

paperwork procedures.
development

or

activities
Therefore
costs

these

Nothing in the definition of research and
the

in

relates

in nature because accompany

to

costs

listing

of

and

development

fees

charged

by

are not considered

research

and development

and are expensed

straight

research

as administrative

costs

when

an

agency.

incurred.

The final area to analyze for FDA costs is whether they should

be expensed or capitalized.
specifically

on this

exactly

the FASB's

the

what

FASB's

opinion

on research

and development

the attempt

to specify

be discussed

later

to the options
COMPANY

which

makes
would
and

it difficult

to determine

be on this matter
development

costs

although,
was

stated

This discussion relates to the explanation of when

earlier.

research

opinion

issue

No articles have been published

costs

can be capitalized

definite

along

with

future

benefits.

the different

of capitalization

which
This

alternatives

leads

topic

to

will

relating

or expensing.

DATA

The third
of the treatment

and background

section

of FDA approval

brings

in specific

costs by various
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examples

companies.

When

looking at the companies for which I have collected data,

the

general consensus seems to be expensing of research and development
costs along with the costs associated with FDA approval.

The data

collected is from financial statements, notes to the financial
statements, and managers notes.
I took a sample of fifteen

that have extensive
experiencing
the companies

financial

statements

research and development

costs and are also

an increase in FDA approval costs.
financial

statements

from companies

Insertions from

are found in Appendix

C.

I will

refer to a few that have significant information.
The first company

Inc.

This

products

company

to treat

neurological

to be investigated

"engages

in the development

or prevent

diseases

is Houston

a variety

Biotechnology

of pharmaceutical

of common

and disorders. "(Financial

ophthalmic

Footnotes)

and
Their

products involve a high degree of risk and uncertainty and
therefore

require

resources

before

Commercialization
take

many

a

investment

the product
requires

years.

Biotechnology

large

Inc. will

can enter

FDA approval

Because

of

not

in

the

the

and

technical

commercial

on the products

risk

realize

cash

and

which

uncertainty,

its research

market.
can

Houston

and development

investment until the FDA gives approval to market the drug and
profi ts
company

are

at

does not measure

is approved
costs when
The

generated

for market,
incurred,

second

a future

or realize
they

is

Pharmaceutical

since

this

until the product

all research

FDA approval
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Therefore,

an investment

expense

including

company

date.

and development

costs.
Resources

Inc.

This

company

primarily

pharmaceuticals,

and

manufactures

distributes

mainly the oral solid form(tablet

generic

and capsule).

At their financial statement date, they were waiting for FDA
approval

on one

submi tting

product

line.

The

FDA

insisted

any more new drug applications

that

they

avoid

until the FDA has a

chance to perform a validity assessment program on those current
products waiting FDA approval.

Because a management is unable to

predict what the outcomes of this program will have on the product
lines

or operations

are incurred.
states,

in general,

they

As the definition

Pharmaceutical

expense

of research

Resources

Inc.' s

all costs

when

and development

costs

must

be

they
costs

expensed

since they are unable to define the value of the benefits they may
receive.

The third and company is Helix Biocore,

operates in the
production

Inc.

cardiovascular field, more

and development

of heart valves.

This company

specifically the

The unusual

aspect

of

this company is that they are able to give a definite estimate of
future

benefits.

They

"today, estimates
$410 million."
will

be

Helix

approval.

research
have

at

go on to state
first

Biocore,

and development

a valid

in their

1992

financial

statements:

are that the world market for heart valves is

They

limited

state

argument

I feel that the reason

that the United

because

Inc.

they

decided

costs as incurred,
if they

wanted

they expense

still

to

States

must

obtain

expense

even though

to capitalized

market

all

FDA

their

they would

their

their costs is because

costs.

it's the

norm to treat research and development costs in that manner, and
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also because they must still obtain FDA approval in the United
States.

Since the costs of FDA approval are enormous and difficult

to estimate, it was easier to expense all the costs associated with
research and development.
After reviewing my sample of financial statements, I reached
the conclusion that all the companies I looked at expensed their
research and development costs, which includes their FDA approval
costs.

The most commonly

stated reasons were the inability

measure the possible future benefits of

their

to

research and

development investments and to determine if their product will
receive FDA approval.
financial statements.

Appendix B recaps the conclusions of the
It shows the reasons the companies give for

their

treatment

of research,

development,

their

treatment

is for research,

and FDA costs,

development,

and what

and FDA costs.

The next section of the paper will consider the reporting
alternatives.
ALTERNATIVES
There

development
alternative
costs

are two alternative

costs

mainly

is to treat

as expenses.

as to the treatment

the

costs

research,

The other

of

FDA

development,

alternative

of research

approval.
and

is to treat

FDA

and

One

approval

these

as assets and capitalize the costs over a number of years.

costs

The

FASB's definition of research and development costs is narrow
meaning it does not allow many companies to treat the research and
development

costs as assets,

revenue-producing

assets.

when actually

The
20

FASB

these costs often become

makes

no

mention

of

FDA

approval

costs;

it never

addresses

the issue.

It is the companies

and accountants responsibility to determine if these FDA approval
costs can be considered assets or expenses.
EXPENSES

The majority, if
companies

I reviewed)

treated

and development

approval

costs

category

are considered

development costs.
to expense

their

companies(especially the

research

and development

They included their costs of FDA approval

as expenses.
research

not all, the

which

the

is appropriate

costs

in the

because

FDA

"final end" of research

and

The question is why do all the companies choose

the enormous

costs associated

costs

as assets

with FDA approval

would

when the

treatment

of these

be more beneficial

to the

company?

The answer is the rules and guidelines set by the FASB.

As mentioned in the background section, the FASB's reasons for
treating the majority of research and development costs as expenses
were stated,

costs.
future

along with the strict

The five reasons
benefits;

expendi tures

concept

opposition

stated

again are:

2) Lack of causal

and

benefits;

of an asset;

r e 1 at ion

3) R&D

4) Matching

does

not

to this treatment

of

"1) Uncertainty

of

between

s hip
meet

of revenues

the

accounting

and expenses;

5)

Relevance of resulting information for investment and credit
decisions."

(Bierman

FDA approval
costs,

costs

the FASB

the reasons
determine

48)

Because

it was previously

are considered

part of research

guidelines

are applicable
if a company's

also apply
in this
product
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that

and development

to FDA approval

situation.
will

determined

costs.

It is difficult

be approved,

much

less

All
to
to

determine what the expected benefit will be.
the

relationship

between

FDA

approval

costs

drugs cannot be marketed unless they
therefore

the expenditures

is not approved,
a good reason

there

provide

costs

and

a benefit,

should

although

approval,
if the drug

This information

be treated

Many

benefits.

receive FDA

is no relationship.

why these

It is easier to see

gives

as expenses.

Another important factor why FDA costs should be expensed is
conservatism.

When dealing with FDA costs, a company cannot be

certain that they will receive FDA approval much less when they

This involves a great deal of

will receive that approval.
uncertainty.

It is safe and more conservative to give the expected

value of research,
thereby

expensing

development,
all

the

and FDA costs a value of zero,

costs

they

incur.

(Bierman

This

48)

treatment avoids making many adjustments if the FDA doesn't approve
the product or the research and development does not produce any
revenues.

One
expenses

area

of

are

the

FDA

costs

newly

that

adopted

should
user

always

fees.

be

considered

These

costs

are

administrative in nature because they are costs attached to the use
of facilities

and applications.

They are a set amount

and are the

same for every product

no matter how long the approval process

lasts nor how much money

the company

not considered

part of the definition

and

not

therefore

part

of the

they will always be treated
other

has.

of research

definition

as expenses

FDA costs.
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Because

of FDA

these

costs

are

and development,
approval

and separated

costs,

from the

Expensing FDA costs is not only more conservative, it is also

There is no need to calculate and determine

simpler to apply.
amortization

The FASB only requires brief disclosure

amounts.

and

development

expenses,

including

FDA

regarding

research

expenses.

The disclosure could be as brief as one line on the

income statement listing research and development expenses for the
year to paragraphs explaining what the research, development,

and

FDA costs are for and what they consist of.
The previous

factors

are the reasons

why FDA costs

should

expensed or why it would be beneficial to expense the costs.

be

It

seems to be the alternative most companies tend to follow.

ASSETS
The other alternative

is that of treating

which is the least common alternative.

FDA costs as assets,

Many opinions back this

alternative because it seems to be the better approach for
companies

to follow.

The reason most commonly stated in accordance with the asset
alternative

Once again, the

is that of the matching principle.

matching principle states that expenses should be matched against
the revenues in the period the revenues are earned.
FDA approval

Maurice
created
when

the

costs,

S. Newman
and these

said for FDA costs.
the product.

this could be a time period

of over ten years.

states

sense,

costs

R&D brings

In the case of

"in an accounting

should

forth

be matched

fruit."

(Newman

against
6)

assets

future

are

revenues

The same could be

FDA costs produce assets if the FDA approves

The revenues

produced
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by products

with

FDA approval

cannot be offset by expenses of the products because the expenses

were incurred probably many years before and have already been
removed from the income statement.
Related to the matching principle is the length of time and
the amount

of cash investment

required

for FDA approval.

In 1991,

it took an average of three years for the FDA to approve a drug

(FDA approval stage
average

of twelve

(Hanson

28)

approval

begins

being

to

million

compete

the

of money

and quickly

pharmaceutical
(Ember

6)

to expense

needed

increases,

for one product.

$8 billion.

amount

and it took an

to get the drug from the lab to the market.

at $125 million

$400

approximately
enormous

years

The amount of cash investment

around

order

one of the last phases),

-

It was

industry

to gain FDA
the average
said

that

will

in

invest

This is a long time and an

every year.

It would make more

sense to capitalize the costs and spread they out evenly over the
life of the product.

If in the future

there were more cost than revenues,
Ellis and McDonald

it is determined

then expense

have an opinion

the excess

that says

this erroneous focus is that growth-enhancing

that

the

costs.

"a consequence

of

activities such as

R&D, market development, and manufacturing development, are treated
as expenses

to be minimized

(Ellis 31)

They make a valid point about the economics of product

development.

rather than investments

We as consumers want companies to develop new and

better

products

prefer

that the costs be kept down so all consumers

the

new

in the future."

to increase

technology.

our

quality

of life.

We would
could

also

share

in

When companies have to expense all their
24

costs, these costs are passed on to the consumer, whereas if they
were

capitalized

therefore

the

companies

would

have

less costs to the consumers.

saying that all projects should be

less

expenses

and

This statement is not
considered valid and be

capitalized, yet it is implying that projects be analyzed more
closely to determine if they have a good chance of being approved
by the FDA.

then

If the product does have a good chance of approval,

determine

marketplace.
current

If this

company

relating

if

the

product

favorable

information,

to FDA approval,

will

outcome

be

profitable

in

can be concluded

the product

costs,

should be capitalized.

the

from the

especially

those

If the product

is

terminated before it is placed on the market or before FDA
approval, then all the costs can be expensed.
More disclosure is required for treating FDA approval costs as
assets.
of the

In the financial
asset

notes

to

and

the

the

statements

amount

financial

capitalization

schedule

asset being capitalized.

that

a company
has

statements

been

a

must

show the value

capitalized.

company

and give a detailed

must

In the
show

description

the

of the

FDA approval could be considered an asset

because it most often provides for future economic benefit.

If a

product

that

gains

the product

FDA approval,

will

it is almost

100 percent

certain

be marketed.

The previous paragraphs gave reasons in favor of treating FDA
approval

costs

as assets.

It is probably the most practical

solution for most companies to adopt.
least

common

approach

to utilize.
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Unfortunately it is also the

As can be determined from the arguments stated above, there is

a thin line between treating FDA approval costs as expenses or
assets.

Just because one method is more common does not mean that

the method is the best for that company.

Which

al ternati ve

a

company uses usually depends on how they fit the FASB's guidelines
for research and development costs.
RECOMMENDATIONS
In my

opinion,

development

cost

restrictions,

FDA

approval

should

but

these

be

costs,

along

capitalized.

restrictions

with

There

should

research

and

should still be

be narrowed

allowing

for more cost to be capitalized, thereby fueling the economy for
additional research and development leading to FDA approvals.

In many cases companies will not enter a research and
development/FDA project unless they are sure of success.
perform many tests

-

analysis

can usually

a company

project

will

always

100 percent

provides

succeed

a valid

This provides
approval

scientific

accurate,

support

enter a multi-million

Granted

yet

that

are

this

theory

not,

of whether

picture

the

is not

consistent

and

of the project.

of the treatment

for the most

dollar project

preliminary

analysis

it is highly

of the overall

for the asset

Companies

Through

get a good indication

or fail.

estimation

costs.

and financial.

They can

part,

of FDA

going

to

blind.

For this reason I
recommend that companies put additional pressure on the FASB for a

change

in

development

their
costs.

of FDA approval

accounting

policy

In particular

regarding

the FASB should

costs.
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research

address

and

the area

Another recommendation is to consider selling the product
under review in foreign countries who do not have as strict of
regulations

as

the

United

demonstrated

by Biospherics,

States
Inc.

does.
They

This

decided

approach

to

is

sell/release

drugs in other countries to generate the revenues needed for them
to gain FDA approval in the United States.

This approach would be

useful after extensive testing of the drug has been completed so

that the possibility of harm to consumers using the product is
decreased.

A new approach was recommended by David E. and Paul E. Nix in

their article

"Its Time to

Change the Financial Accounting

Treatment of R&D Expenditures."
contra-stockholder's

In their approach they utilize a

equity account that is considered a permanent

account appearing on the balance sheet as a deduction from
stockholder's equity.

They proposed to capitalize all research and

development expenditures as incurred during the year in this
contra-stockholder's

equity

account (unless the expenditures

had

absolutely no future benefits in which case they would be expensed
At year-end,

immediately)

.

balance

the

in

contra

development

expenditures

This

result

could

development,

in

a fixed

account
would

a

from

percent
prior

be expensed

greater

and even FDA approval,

of

years

the

remaining

research

for the current

emphasis

of products

on

year.

research

because

and

and

none of the

current years research and development expenses would be reported
on this years financial statements.
According

to the authors

of the article,
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"the advantages

of

APPENDIX

R & D ACTIVITIES

A

ACTIVITIES

NOT CONSIDERED

R & D

a) Laboratory research aimed at
discovery of new knowledge.

a) Engineering follow-through
in
any
early
phase
of
commercial production.

b) Searching for applications
of new research findings.

b)
Quali ty
control
during
commercial production including
routine testing.

c) Conceptual
formulation
and
design of possible
product or
process alternatives.

c) Trouble-shooting
during production.

d) Testing in search for or
evaluation of
product
or
process alternatives.

d) Routine, on-going efforts to
refine, enrich, or improve the
qualities
of
an
existing

e) Modification
of the design
of a product or process.

product.

e) Adaptation of an existing
capability
to a particular

f) Design, construction, and
testing
of
pre-production
prototypes and models.

requirement

Engineering

(from Kieso

activity

tools,

equipment.

i) Legal work
on patent
applications, sale, licensing,
or litigation.

stage.

and Weygandt

to

h) Activity, including design
and construction
engineering
related to the construction,
relocation, rearrangement, or
start-up
of
facilities
or

required to advance the design
of
a
product
to
the
manufacturing

need.

changes

g) Routine design of
jigs, molds, and dies.

h) Design, construction, and
operation of a pilot plan not
useful
for
commercial
production

~

or customer's

f) Periodic design
existing products.

g) Design
of tools,
jigs,
molds, and dies involving new
technology.

i

breakdowns

608)
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APPENDIX

COMPANY

NAME

B

FDA COSTS

REASON FOR TREATMENT

MEDCO RESEARCH

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

BARR
LABORATORIES

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

HELIX BIOCORE

EXPENSE

ABLE TO ESTIMATE FUTURE
BENEFITS - CHOOSE TO EXPENSE

GULL
LABORATORIES

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

STAAR SURGICAL

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

VISX

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

K V
PHARMACEUTICAL

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

A L LABORATORIES

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

DOW CORNING

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

BIOPHAMACEUTICS

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

PHARMACEUTICAL
RESOURCES

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

HOUSTON BIOTECH

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

HALSEY DRUG

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

BIOSPERICS

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS

UNIVERSITY
PATENTS

EXPENSE

UNABLE TO ESTIMATE FUTURE
BENEFITS
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APPENDIX
BARR LABORATORIES

C

INC

BARR LABORATORIES,
INC. AND SUBSIDIARIES
Consolidated
Statements
of Operations
Years ended June 30, 1992, 1991 and 1990

1992
Net sales (including
sales to related
parties of $2,842,000
in 1992,
$1,938,000
in 1991 and $1,165,000
in 1990) (note 8)
100,790,419
Costs and expenses:
Cost of sales (note 5)
70,595,112
Distribution
3,413,237
Marketing
and sales
6,756,290
Research and development
7,436,027
General and administrative
12,403,294
Interest expenses
2,165,265
Other expense
(income), net (note
10)
1,485,182
Earnings
(loss) before income tax
expense
(benefit)
-3,463,988
Income tax expense
(benefit)
(note
6)
-1,555,000
(loss)
-1,908,988
,Net earnings
See accompanying notes to consolidated
financial

1991

1990

93,984,088

70,305,651

60,686,779
3,132,698
5,981,440
5,908,793
9,506,368
1,716,187

48,699,168
2,911,554
4,289,990
3,965,961
5,567,896
1,944,951

-3,788

1,398,396

7,055,611

1,527,735

2,531,000
4,524,611
statements.

451,000
1,076,735

(e) Research and Development-Research
and development
costs, which consists
principally
of product development
costs, are charged to operations
as
incurred.
(12) Other Matters-Food
and Drug Administration
(FDA) Litigation-After
completion
of lengthy inspections
of the Company's
facilities
in the fall of
1991 and again in the spring of 1992, the FDA determined
that the Company was
not in compliance
with current good manufacturing
practice regulations
(cGMP).
Upon learning of the FDA's position,
the Company vigorously
disputed the
findings because it believed that it was in substantial
compliance
with all
applicable
regulations.
Furthermore,
the Company did not believe that the FDA
had the right to impose certain sanctions which are imposed automatically
when
a company is deemed to be out of compliance with cGMP regulations.
Although the
parties met numerous times to discuss the issues raised by the FDA and the
Company, those discussions
were not fruitful because of the insistence
by the
FDA that the Company agree at the outset to a consent decree which would have
caused the Company to cease all operations
until such time as the alleged
deficiencies
had been remedied to the FDA's satisfaction.
When it became clear that the Company and the FDA would not be able to
negotiate
an end to their dispute, the Company undertook
several actions.
First, in an effort to reach a swift settlement
with the FDA and address its
regulatory
and compliance
issues, the Company temporarily
reduced its product
line in April 1992. This reduction resulted in the suspension
of the marketing
of a significant
number of the Company's
products.
The Company believes that
all of its products,
including those that were suspended,
are safe and
effective
for their intended use and conform to all applicable
pharmaceutical
industry standards.
Second, in April 1992, the Company commenced an action in Federal District
Court in Newark, New Jersey (the Barr Action) seeking judicial clarification
of
Barr's cGMP obligations
and an injunction
preventing
the FDA from enforcing
ambiguous
and shifting interpretations
of the cGMP regulations.
In addition,
the Company is seeking a judicial declaration
that the FDA's Alert List and the
corresponding
sanctions imposed upon the Company by the FDA associated with the
Alert List are illegal. The Company has moved for a preliminary
injunction
against its inclusion on the Alert List and the sanctions imposed by the FDA as
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a result of being included on
As of the date hereof, the
currently
available,
it is not
these actions on the Company's

the Alert List.
cases are ongoing and,
based on the information
possible to determine
financial position or the possible effect of
results of operations.

PRESIDENT'S
LETTER:
(FROM ANNUAL REPORT TO SHAREHOLDERS)
DEAR FELLOW SHAREHOLDER:
Optimism
is high at the Company for a number of reasons.
First, the
Company is poised to take advantage of new opportunities
emerging
in the
generic marketplace.
Because of FDA's new interpretation
of old regulations
and the increasing
costs of regulatory
compliance,
many of our traditional
competitors
are being forced to close their doors.
FDA's actions have not
only reduced the number of competitors
but also ensured that the new generic
marketplace
will remain small.
Barr Laboratories
is far ahead of its
remaining
competitors
vis-a-vis
these "new" regulations.
This, combined with
our production
capacity and ability to produce high quality pharmaceuticals,
provides the Company with an enormous strategic
advantage.
Secondly,
the Company continues
to develop new products.
Our research
and development
activities,
while having slowed during the dispute with FDA,
will be back in full operation
shortly.
In addition, the Company is
currently
awaiting approval from FDA to market a significant
number of new
products.
Although
it is not possible to predict when these new approvals
will be granted to FDA, we are optimistic
that following the resolution
of
the legal proceedings
between Barr and FDA, approvals
for these new
applications
will be forthcoming.
Lastly, as shareholders
of Barr Laboratories,
Inc., you can be proud of
the effort and commitment
of our highly skilled work force.
Their efforts,
not only in production,
scientific
and marketing
achievements,
but those
required during our ongoing dispute with FDA, have truly been extraordinary.
Research and development
expenses for the fiscal year ended June 30, 1992
were $7,436,027,
compared to $5,908,793
for the comparable
period last year.
This increase of 25.8% is primarily
attributable
to increases
in salaries. The
Company also increased
staff and incurred additional
regulatory
compliance
expenses.
Research and development
expenses were $5,908,793 or 6.3% of net sales for
the fiscal year ended June 30, 1991 as compared to $3,965,961
or 5.6% of net
sales for the fiscal year ended June 30, 1990.
This increase of 49.0% is
primarily
attributed
to an increase in outside clinical studies, salaries and
raw material
consumed in the development
of new products.

BIOPBARMACEUTICS

IRC

BIOPHARMACEUTICS,
INC.
CONSOLIDATED
STATEMENTS
OF OPERATIONS
Years ended September
30

Sales
Costs and expenses:
Cost of sales
Selling, general and administrative
Research and development
Interest

Other income (deductions):
Gain on sale of equipment
Settlement
of claims with affiliate
and past management
(Note 14)
Recovery
(write-off)
of:
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1992
2,375,371

1991
6,244,443

3,008,651
974,956
NA
258,140
4,241,747
-1,866,376

5,823,758
1,216,344
NA
235,268
7,275,370
-1,030,927

75,751

NA

NA

1,078,752

NA

NA

1990
5,599,861
5,186,242
1,113,632
90,467
164,996
6,555,337
-955,476

Goodwill
(Note 15)
Drug licensing
receivable

(Note

16)

Loss from continuing
operations
Loss from discontinued
operations
(Note 3)
Net loss
Primary loss per share (Note 10):
Continuing
operations
Discontinued
operations
Net loss
The accompanying
notes are an integral

NA
NA
1,154,503
-711,873

NA
69,945
69,945
-960,982

-473,483
-104,950
-578,433
-1,533,909

NA
-711,873

NA
-960,982

-808,006
-2,341,915

-.09
-.12
-.18
NA
NA
-.10
-.09
-.12
-.28
part of these financial statements.

FINANCIAL
FOOTNOTES:
-NOTES TO CONSOLIDATED
FINANCIAL
STATEMENTS
f. Research
and development
expenses-The
Company expenses research and
development
costs as incurred.
Note 2. Basis of Preparation-The
Company has incurred losses in six
consecutive
years, which have resulted in a decline in stockholders'
equity to
a deficit of approximately
$453,000 at September
30, 1992.
On January 10, 1992, the Company was approved to commence operations
as a
drug repacker, after being shut-down for approximately
two months in compliance
with a temporary restraining
order obtained by the Food and Drug Administration
("FDA") on November
1, 1991.
The Company is currently
seeking approval to
resume its manufacturing
operations
pursuant to an amended decree of permanent
injunction
for alleged current good manufacturing
practice deficiencies
in its
drug manufacturing
activities.
Upon achieving this approval,
the Company
intends to develop prescription
products which do not require the approval of
the FDA, but carry higher profit margins than the over-the-counter
products
previously
sold by the Company. In addition, the Company plans to apply for FDA
approval of prescription
drugs, which both require bioavailability
studies or
do not require bioavailability
studies.
BIOSPHERICS
IRC
Consolidated
Years ended

Statements
of Operations
December
31

1992
Revenues
Contract revenues
(Note 1)
Product and process sales
Total revenues
Costs and Expenses Operating
Expenses
Direct costs and operating
expenses,
excluding
depreciation
and
amortization
Selling, general and administrative
Research and development
Depreciation
and amortization
(Note 4)
Uncollectible
accounts
Total operating
expenses
Income from operations
Other Income (Expenses)
Other income (Note 11)
Interest expense
Income before income taxes and
extraordinary
item
Provision
for income taxes (Note 6)
Income before extraordinary
item
Extraordinary
item (Note 9)
Net Income
The accompanying
notes are an integral
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1991

16,685,489
47,085
16,732,574

15,096,221
29,096
15,125,317

13,215,878
1,832,016
58,293

12,385,697
1,773,428
250,094

581,172
20,000
15,707,359
1,025,215

582,058
52,000
15,043,277
82,040

103,577
-87,342

438,477
-177,087

1,041,450
343,430
360,703
137,371
680,747
206,059
NA
-76,429
680,747
129,632
part of the financial statements

MANAGEMENT
DISCUSSION:
ITEM 6. Management's
Discussion of Financial Condition and Results of Operations
The BioTech Programs Unit generated
revenues from royalties
and sales of its
specialty
chemicals
of $149,000 in 1992, compared with $467,000 in 1991.
Research and Development
expenditures
were $270,000 and $250,000 for 1992 and
1991, respectively.
The spending in 1992 was related to new studies in support
of its patented nonfattening
sugar, D-tagatose,
and safe-for-humans
pesticide.
There are a number of factors that could potentially
have a significant
impact on future earnings and the financial
condition
of the Company.
As
previously
discussed
in Item 1, the Company is continuing
its effort to bring Dtagatose and the safe-for-humans
pesticide to market.
Research and Development
costs are expected to increase in 1993 as part of this effort. Full-scale
toxicity test on D-tagatose
have begun, which, upon completion,
should clear
the way for sales of the product overseas.
Profits generated
from these sales
will be utilized to fund the testing necessary
to obtain FDA approval,
thus
opening the U.S. market.
Cash generated
from operations
will continue to be utilized to fund the
ongoing research and development
effort.
An example of this was the Company's
ability to fund the full-scale
toxicology
test for D-tagatose
in the first
quarter of 1993.
Consistent
with the Company's policy, excess profits will be
retained within the Company to help bring these products to market.
DOW CORNING

CORP

DOW CORNING CORPORATION
CONSOLIDATED
STATEMENTS
(in millions
of dollars
Year ended December 31

OF OPERATIONS
AND RETAINED
except per share amounts)

NET SALES
OPERATING
COSTS AND EXPENSES:
Manufacturing
cost of sales
Marketing
and administrative
expenses
Implant costs
Special items

EARNINGS

1992
1,955.7

1991
1,845.4

1990
1,718.2

1,343.2
410.4
69.0
40.0
1,862.6
93.1

1,195.5
397.3
25.0
29.0
1,646.8
198.6

1,105.2
351. 6
NA
NA
1,456.8
261. 5

OPERATING
INCOME
OTHER INCOME (EXPENSE):
Interest income, currency gains
(losses) and other, net
-20.6
31.9
18.2
Interest expense
-22.5
-21. 5
-18.7
INCOME BEFORE INCOME TAXES
50.0
209.0
261. 0
Income taxes
10.1
58.3
80.1
Minority
interests'
share in income
11.5
14.1
9.8
INCOME BEFORE CUMULATIVE
EFFECTS OF
CHANGES IN ACCOUNTING
PRINCIPLES
(1992 - $11.36 per share;
1991 - $54.64 per share;
1990 - $68.44 per share)
28.4
136.6
171.1
NET INCOME (LOSS) (1992 - $(28.80)
per share; 1991 - $61.16 per share;
1990 - $68.44 per share)
-72.0
152.9
171.1
The Notes to Consolidated
Financial
Statements
are an integral part of these
financial
statements.
FINANCIAL
FOOTNOTES:
-NOTES TO CONSOLIDATED
FINANCIAL
STATEMENTS
Research and Development
Costs-Research
and development
costs are charged
to operations
when incurred and are included in manufacturing
cost of sales.
These costs totalled
$161.2 in 1992, $148.7 in 1991 and $139.8 in 1990.
NOTE 2 - CONTINGENCIES-Breast Implant Business-Prior to January 6, 1992,
the Company, directly and through its wholly-owned
subsidiary,
Dow Corning
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Wright Corporation,
was engaged in the manufacture
and sale of silicone gel
breast implants. As part of a process initiated in 1991 of review by the United
States Food and Drug Administration
(FDA) of Premarket Approval Applications
(PMAA) for silicone gel breast implants, on January 6, 1992 the FDA asked
breast implant producers
and medical practitioners
to halt the sale and use of
silicone gel breast implants, pending further review of the safety and
effectiveness
of such devices, and the Company voluntarily
suspended shipments
of implants.
Subsequently,
the Company announced
that it would not resume the
production
or sale of silicone gel breast implants and that it would withdraw
its PMAA for silicone gel breast implants from consideration
by the FDA.

GULL

LABORATORIES

IRC

Gull Laboratories,
Inc
Consolidated
Statements
of Operations
Years Ended December
31

Sales
Cost of sales

1992
8,606,508
2,964,836
5,641,672

1991
6,492,130
2,324,205
4,167,925

Expenses:
Selling,
general
and administrative
Research and development
Total expenses
Other income (expense):
Interest expense

2,153,000
696,561
2,849,561

1,665,015
582,515
2,247,530

Other

.

Total other income (expense)
Income from continuing
operations
before provision
for income taxes
Income tax provision
(Note 7)
Income from continuing
operations

Discontinued operations

-

-292,778
-7,264
-300,042

2,589,753
854,500
1,735,253

1,620,353
559,000
1,061,353

-670,332
1,064,921

-521,404
539,949

loss of

USANA, Inc. to be spun off (net
of income tax benefit)
(Notes 2
and 7)
Net income (loss)
Earnings
(loss) per share:
Continuing
operations
Discontinued
operations
Earnings per common and common
equivalent
share (Note 10)
See accompanying

-245,482
43,124
-202,358

.32
-.12

.20
-.10

.20

.10

notes.

MANAGEMENT
DISCUSSION:
ITEMS 6: MANAGEMENT'S

DISCUSSION

AND ANALYSIS

OR PLAN OF OPERATIONS

Research and development
costs increased
20% in 1992 from $582,515 to
$696,561.
In 1992 the Company's research and development
efforts decreased
the new ELISA product line was transferred
out of research and development
production.
During 1992 the Company renewed its research and development
efforts to find new test to supplement
its existing product line.

as
to

Research
& development
costs decreased
46% in 1991 to $582,515 compared
with $1,070,055
in 1990.
This decreased
is primarily
due to the successful
completion
of development
of the Company's
new ELISA product line and the
transfer of many of the employees working on the development
project to product
manufacturing.
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HALSEY

DRUG

CO IHC

Halsey Drug Co., Inc. and Subsidiaries
CONSOLIDATED
STATEMENTS
OF EARNINGS
Year ended December
31

Net sales (Note A)
Cost of goods sold
Gross profit
Research and development
Selling, general and administrative
expenses
Provision
for product recall (Note J)
Earnings
from operations
Investment
loss
Interest expense
Earnings before income taxes and
minority
interest
Provision
for income taxes (Notes A
and F)
Earnings before minority
interest
Minority
interest in net loss
(earnings) of subsidiaries
(Note B)
NET EARNINGS
Earnings per common share (Note A)
Average number of outstanding
shares
The accompanying
FINANCIAL

notes

are an integral

1992
49,867,563
35,769,162
14,098,401
1,090,000

1991
37,462,130
27,343,828
10,118,302
783,000

1990
26,354,399
18,615,413
7,738,986
592,000

8,616,274
2,000,000
2,392,127
NA
-372,681

5,722,340
NA
3,612,962
NA
-509,144

4,480,876
NA
2,666,110
-293,689
-558,590

2,019,446

3,103,818

1,813,831

1,128,000
891,446

1,340,000
1,763,818

810,000
1,003,831

36,994
928,440
.13
7,157,871

-36,994
1,726,824
.26
6,579,061

NA
1,003,831
.16
6,356,527

part

of these

statements.

FOOTNOTES:

MANAGEMENT
DISCUSSION:
Item 7. Management's
Discussion
and Analysis of Financial
Condition
and
Results of Operations.
The Company's
continued
increased
sales are linked to expanding
sales of
existing products as no new products were introduced
by the Company in 1992,
although Houba received a supplemental
approval for one new product. The
Company's
increase in sales is a result of increased
sales of previously
existing products through improved marketing and manufacturing
and an expansion
of the Company's
customer base.
Research
and Development
Expenses
Research and development
expenses
for
fiscal years 1992, 1991 and 1990 were approximately
$1,090,237,
$783,000 and
$592,000,
respectively,
which, expressed
as a percentage
of sales, were 2.2%,
2.1% and 2.3%, respectively.
The Company's
research and development
efforts
during 1992 were predominantly
directed at the development
of Biotin and
Zidovudine
(AZT) raw materials
at the Indiana facility.
The Company has and in
the future will, to the extent possible,
continue to take an aggressive
position in the development
of new products coming off of patent protection
or
expected to become available
in the near future.
The Company also has chemical
products at various stages of development
and production.

HELIX

BIOCORE

IHC

PRESIDENT'S
LETTER:
(FROM ANNUAL REPORT TO SHAREHOLDERS)
To Our Shareholders
and Friends:
And what a year it was.
In 1991, we vigorously
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pursued

our entry

into

the heart valve market.
As you may know, our management
team and employees
have extensive
experience
in the cardiovascular
field, many having been
previously
involved in the development
of implantable
devices,
including
heart valves.
This has allowed us to develop a new heart valve with a new
pivot concept which is designed to reduce thromboembolism
and thrombosis;
problems
long recognized
as the scourge of heart valves.
Under a development
agreement with CarboMedics,
Inc., the world's largest and most experienced
manufacturer
of heart valve components,
we will develop, manufacture
and
market our new open pivot, bileaflet,
pyrolytic
carbon heart valve.
The
design, which is protected
by two issued U.s. patents and six issued overseas
patents together with additional
patent applications,
is being prepared
for
our first human implant which we anticipated
will occur in Europe in the
first half of 1992.
During 1991, we received encouragement
and comments from the medical
community,
which confirms our belief that we will succeed in the heart valve
market.
Let us review some of those thoughts:
Today, estimates
are that the world market for heart valves is $410
million.
Our initial commercial
introduction
into the U.s. market will be
limited, as we must conduct clinical trials and seek FDA regulatory
approval.
In the international
market, however, we feel that we will be able to
introduce our valve and begin to generate revenues in 1992.
MANAGEMENT
DISCUSSION:
ITEM 7. MANAGEMENT'S
DISCUSSION
AND ANALYSIS OF FINANCIAL
CONDITION
AND
RESULTS OF OPERATIONS
Research,
development
and engineering
expenses related to the heart valve
operations
increased by 96% from 1990 ~o 1991.
The increase resulted
from a
full year's development
under the heart valve program which the Company
commenced
in November
1990.
The expenses
incurred in 1991 and 1990 included
$404,331 and $383,000,
respectively,
in payments to outside vendors for
development
work related to the ATS Medical valve.
The Company expects that
research,
development
and engineering
expenses will increase substantially
during 1992 as the Company continues testing of the Valve and meets additional
milestone
for payments to outside vendors.
FINANCIAL

STATEMENT

TEXT:

NA; Income Statement Data provided only for NYSE, AMEX, NASD and Fortune
1,000 companies.
FINANCIAL
FOOTNOTES:
NA; Data provided only

HOUSTON BIOTECHNOLOGY

for NYSE,

AMEX

and Fortune

1,000

companies.

INC

HOUSTON BIOTECHNOLOGY
INCORPORATED
STATEMENTS
OF OPERATIONS
Year Ended December 31
REVENUES:
Research and development
contracts:
Houston Biotech Partners,
L.P.
Other
Investment
income
Other income
Total revenues
COSTS AND EXPENSES:
Research and development
contract
Research and development
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1992

1991

1990

1,067,469
NA
159,778
237,831
1,465,078

2,813,027
NA
142,934
104,984
3,060,945

2,986,906
1,000,000
119,306
88,557
4,194,769

981,541

2,590,938

2,755,350

proprietary
General and administrative
Writedown
of capitalized
construction
costs
Total costs and expenses
INCOME (LOSS), before income taxes
and extraordinary
item
Income taxes
INCOME (LOSS), before extraordinary

item

.

EXTRAORDINARY
ITEM, utilization
of
net operating
loss carryforward
NET INCOME (LOSS)
The accompanying
notes are an integral

2,013,261
719,452

247,958
330,640

535,933
287,616

43,834
3,758,088

NA
3,169,536

455,363
4,034,262

-2,293,010
NA

-108,591
NA

160,507
59,940

-2,293,010

-108,591

100,567

NA
NA
59,940
-2,293,010
-108,591
160,507
part of these financial statements.

FINANCIAL
FOOTNOTES:
--(1) Organization-HBI
is a biotechnology
company engaged in
the development
of pharmaceutical
products to treat or prevent a variety of
common ophthalmic
and neurological
diseases and disorders,
with a primary focus
in ophthalmology.
The principal
objective
of the Company is to 'develop
biopharmaceutical
products to treat conditions
for which no effective
pharmaceutical
treatment
is currently available or for which such products may
provide advantages
over existing treatments.
The Company's
most advanced
product is an immunotoxin
for the prevention
of secondary cataract
(the "4197XRA Immunotoxin").
Until April 30, 1992, substantially
all of the Company's
research and
development
activities
related to contract research performed
for Houston
Biotech Partners,
L.P. (the "Partnership"),
a research and development
partnership.
Revenues resulting
from the 4197X-RA Immunotoxin
had not commenced
as of
December
31, 1992, and are not expected to do so, if at all, for at least
several years. Development
of pharmaceutical
products takes many years and
involves a high degree of risk and uncertainty.
There can be no assurance that
any revenues will ever be generated
from development
efforts.
In addition,
it
is probable that current funds available to invest in research and development
will be insufficient
to complete the 4197X-RA Immunotoxin
to commercialization.
Contract Research Revenues-Contract
research revenues consist of
nonrefundable
amounts earned under contractual
agreements
to perform research
and development
of specific scientific projects and are recognized
as revenues
as the research
is performed
or as milestones
are achieved
(see Note 3). As a
result of the Combination,
contract research is no longer conducted
on behalf
of the Partnership,
and therefore
contract research revenues related to
contract research on behalf of the Partnership
were no longer recognized.
Research and Development
Costs-HBI performed contract research on behalf of
the Partnership
through April 30, 1992, as well as its own independent
proprietary
research.
Research and development
costs are expensed when
incurred. These costs consist of direct costs associated with specific projects
including
costs associated
with the operation
of laboratories
performing
such
research,
and in the case of contract research,
an allocation
of general and
administrative
costs associated
with administering
these activities.
As a
result of the Combination,
contract research
is no longer conducted
on behalf
of the Partnership,
and therefore
HBI no longer allocated
general and
administrative
costs. See Note 10.
MANAGEMENT
DISCUSSION:
ITEM 7. MANAGEMENT'S
DISCUSSION
AND ANALYSIS OF FINANCIAL
CONDITION AND
RESULTS OF OPERATIONS
The following
discussion
and analysis should be read in conjunction
with
the Financial
Statements
and related notes contained
elsewhere
herein.
Product Development
Development
of biopharmaceutical
products
involves a
high degree of risk and uncertainty
and requires a large investment of cash and
technical resources before commercialization.
The Company's realization
of its
investment
in its research and development
efforts will not occur unless and

38

until regulatory
approval to market is obtained and profits are generated
at a
future date.
The FDA requires compliance
with strict regulatory
procedures
before it will grant approval for a pharmaceutical
product to be marketed
in
the United States.
These regulatory
procedures
require, among other things:
(i) preclinical
development
and filing an IND with the FDA, (ii) Phase I human
clinical trials to test safety, which normally take from one to three years,
(iii) Phase II and III human clinical trials to confirm the results of Phase I
safety studies, prove efficacy and observe any low-incidence
adverse effects,
which normally take from two to three years each, and (iv) filing a PLA with
the FDA containing
the results of the human clinical trials for review and
approval by the FDA, a process which normally takes approximately
two to three
years. There is no assurance
that FDA approval of the 4197X-RA Immunotoxin
or
any product candidate
can be obtained within these time frames, if at all.
The Company filed the IND with respect to the 4197X-RA Immunotoxin
in
August 1990, filed a Phase I report with the FDA in January 1992 and commenced
a Phase I/II human clinical study in April 1992.
Primarily
becaus~ of an
unacceptable
level of patient enrollment
by doctors recruited
by the CRO
engaged by the Company for the purpose, HBI closed its initial investigational
site and terminated
its relationship
with the CRO performing
the study.
HBI
has redesigned
the study to facilitate
patient recruiting
and simplify study
execution
without compromising
patient safety.
Patient enrollment
began in
March 1993.
See "Business-Secondary
Cataract-Human
Clinical Trials."
Operating
expenses for the year ended December 31, 1992 were $3,758,088,
an
18% increase from $3,169,536
incurred in the same period in 1991.
This increase
was due to increased research and development
on Company projects other than th
4197X-RA Immunotoxin
and the writedown
of capitalized
construction
costs.

MEDca RESEARCH INC
Medco Research,
Inc.
Consolidated
Statements
Year Ended August 31
Revenues:
Royalty revenue
Interest income
Other income

(Note

of Operations

5)

Costs and expenses:
Royalty expense
(Note 5)
Research and development
costs
General and administrative
expenses
Income (loss) before income
Provision
for income taxes
Net income (loss)
See accompanying
notes.

taxes

1992

1991

1990

4,782,744
1,295,686
281
6,078,711

2,947,127
108,732
570
3,056,429

777,367
118,657
2,147
898,171

2,391,372
2,160,634
1,088,602
5,640,608
438,103
42,600
395,503

1,473,564
298,286
671,133
2,442,983
613,446
1,950
611,496

388,684
438,023
1,304,079
2,130,786
-1,232,615
1,200
-1,233,815

PRESIDENT'S
LETTER:
(FROM ANNUAL REPORT TO SHAREHOLDERS)
Dear Shareholder:
Medco remains dedicated
to a strategy of identifying
and licensing
additional
pharmaceutical
products of promising
potential.
Approval of Adenoscan(R)
by the Health Protection
Branch of Canada's
Health and Welfare Department
for marketing
in Canada, with commercialization
to commence following the grant of an export license by the U.S. Food and
Drug Administration
to Medco's licensee, Fujisawa USA, Inc.
Continued clinical trials of adenosine (MEDR 640) as a cardioprotectant
in patients who have suffered a heart attack, and initiation
of such trials
in patients who are undergoing
coronary artery bypass surgery
Commencement
of Phase II clinical trials of IPPA, a nuclear cardiac
diagnostic
agent
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Commencement
of Phase I clinical trials of adenosine triphosphate
(ATP),
which is being studied for treatment
of cancer and cancer-related
cachexia
(weight loss and bOdy-wasting
syndrome)
Commencement
of multicenter
clinical trials for the oral antiarrhythmic
drug, NAPA(R),
for the treatment
of two types of arrhythmia
in the atria
(upper chambers of the heart)
Commencement
of development
of Bidil(TM) as a vasodilator
therapeutic
for
patients
suffering
from congestive
heart failure.
With an array of products in the late stages of clinical development,
principally
for the treatment
of cardiovascular
diseases and cancer, we
believe Medco is moving closer to the point of commercial
breakthrough.
We are disappointed
that the Food and Drug Administration
has not yet
approved Adenoscan(R)
in the United States.
Our progress has been delayed by
issues arising from the drug-manufacturing
activities
of Lyphomed
Inc., which
was subsequently
acquired by Fujisawa USA, our Adenoscan(R)
manufacturing
and
marketing
partner.
Fujisawa USA has advised Medco that it is working
diligently
to satisfy any Food and Drug Administration
concerns with respect
to the manufacture
of its products.
MANAGEMENT
DISCUSSION:
ITEM 7. MANAGEMENT'S
DISCUSSION
AND ANALYSIS OF RESULTS OF OPERATIONS
AND
FINANCIAL
CONDITION
During fiscal year 1992, the Company's
principal
activities
consisted
of
the continued
development
of, and regulatory
submissions
for, its adenosine
products and the identification
and acquisition
of new products.
In November
1991, the Company entered into an exclusive
worldwide
license agreement
to
research,
develop, manufacture
and market Bidil for patients with CHF.
In
April 1992, the Company entered into an agreement
for the development
and
marketing of IPPA in the United States.
The Company's research and development
expenses
increased
substantially
in fiscal year 1992 due to acceleration
or
initiation of clinical trials for the development
of MEDR 640, NAPA, ATP, Bidil
and IPPA.
During fiscal year 1991, the Company focused on filing New Drug Submission
applications
to the Canadian Health Protection
Branch (HPB) for Adenocard
and
Adenoscan
and on investigating
potential
new indications
for adenosine.
Attention
was also directed to recruiting
senior staff personnel
and licensing
new products
for development
by the Company. During fiscal year 1991, the
Company entered into an exclusive worldwide
license agreement
to research,
develop, manufacture
and market ATP for use in cancer treatment.
Research and development
costs increased
seven-fold,
from $298,286 to
$2,160,634,
reflecting
the Company's
planned acceleration
of research and
development
activities,
including contract manufacturing
and clinical research
contracts,
for NAPA, ATP, Bidil, IPPA, MEDR 640 and bethanidine
sulfate, and
salary and overhead expenses directly related thereto. Research and development
costs are expected to continue to be substantially
higher than those incurred
in prior years.
Research and development
costs decreased
from $438,023 to $298,286,
a
decrease of 32%, primarily
due to a substantial
reduction
in direct clinical
trial expenses associated
with the completion
of the development
of Adenoscan,
for which an NDA was submitted to the FDA in February 1990. Salary and overhead
expenses directly related to research and development
activities
remained
virtually
unchanged
as the Company focused on (a) preparing
plans for the
clinical development
of several of its other products;
(b) conducting
early
stage clinical trials of selected adenosine
products;
and (c) monitoring
and
updating additional
clinical data relating to Adenoscan,
none of which required
significant
direct clinical trial expense.
Research and development
costs are
expected to increase substantially
during fiscal year 1992 from fiscal year
1991 as the Company begins or accelerates
clinical trials for MEDR 640, NAPA,
ATP, Bidil, IPPA, bethanidine
sulfate, MEDR 340 and MEDR 240.
The Company is continuing
with its planned acceleration
of the development
of its products by significantly
increasing
its research and development
expenditures
for preclinical
development
activities and clinical testing of its
products
and the recruitment
of additional
scientific,
administrative
and
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support personnel.
Accordingly,
until such time as Adenoscan
is approved by
the FDA and marketing
of this products commences,
the acceleration
of research
and development
will have a material affect of the Company's earnings and could
result in reduced net income or net losses in the future.
The Company is also
exploring
the possibility
of developing
within the next several years a
limited, specialized
sales force for the marketing of certain of its products,
which would require significant
additional
expenditures.
The Company believes
that it has more than sufficient
cash reserves to fund its current operations,
including the accelerated
development
of its products,
the recruitment
of
additional
personnel
and the development
of a limited sales force as described
above.
Except for Adenocard,
which has been approved and marketed
in the United
States, the United Kingdom and Switzerland,
the Company will not generate
revenues from its products until it receives approval from the FDA or
corresponding
agencies in other countries to market these products.
In October
1992 the Canadian Health Protection
Branch ("HPB") approved the marketing
of
Adenoscan
in Canada.
Commercialization
of this drug in that country will not
commence until the FDA grants an export license for the manufacture
of this
product by Fujisawa USA, which must resolve certain of the manufacturing
issues
with the FDA referred to below the license will be granted.
The FDA's review
of the Adenoscan
NDA has been delayed as the result of certain manufacturing
issues raised by the FDA with respect to various products
including Adenoscan
manufactured
by Lyphomed,
Inc.
(the Company's
original manufacturing
and
marketing
partner for adenosine products which was acquired by Fujisawa USA in
April 1990.)
Fujisawa has advised the Company that it has successfully
completed its internal validity assessment of the Adenoscan manufacturing
data,
and that it is working diligently
with the FDA to resolve the outstanding
issues with the FDA so that the FDA can then complete its review of the NDA.
It is possible, however, that delays in resolving these issues, including those
relating to other Fujisawa products,
could affect the timing of any FDA
approval of the Adenoscan
NDA.
As with any new drug, including
those currently
under development
by the
Company, the Company cannot predict the research
results or the timing of any
potential
marketing
approval,
nor can assurances
be given that the FDA or
corresponding
agencies
in other countries
will approve
any of the Company's
products.
FINANCIAL
FOOTNOTES:
5. Patent, Trademark
and Distribution
Rights-The
Company is engaged in the
development
of new prescription
drugs in pursuit of obtaining
governmental
marketing
approvals
in the United States and other countries.
The Company
acquires exclusive
rights to develop and market various drugs from third
parties,
including related patents and trademarks
(where applicable),
and
develops drugs and seeks patents and trademarks
for its products on a
proprietary
basis. The costs of acquiring
rights from third parties and major
costs associated
with the perfection
and protection
of patents and trademarks
are capitalized
by the Company. Agreements
under which the Company acquires
such rights from third parties generally
require the Company to finance the
costs of clinical trials and the filing of New Drug Applications
(NDAs) with
the United States Food and Drug Administration
(FDA) and, in some instances,
comparable
applications
with appropriate
regulatory
agencies in other
countries.
The Company is also typically
required to pay royalties
to such
third parties based on sales of the applicable
approved drugs and, pursuant to
certain agreements
and under certain circumstances,
the Company is obligated to
make advance royalty payments to such third parties.
In October 1989, the Company received FDA approval to market Adenocard(R)
in the United States. The Company entered into agreements
with Fujisawa USA,
Inc. (Fujisawa) for the manufacture
and marketing of Adenocard(R)
in the United
StateS and Canada.

PHARMACEUTICAL

RESOURCES IRC
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CONSOLIDATED
STATEMENTS
OF OPERATIONS
Year Ended October 3, 1992

AND RETAINED

(DEFICIT)

Oct 3 1992 Sep 28 1991
52,493,000
34,226,000
142,000
649,000
52,635,000
34,875,000

Net sales
Other income
Total revenues
Costs and expenses:
Cost of goods sold
Product development
Selling, general and administrative
Interest
Settlements
of legal proceedings
Regulatory
review costs, recalls
and other matters
Income (loss) from continuing
operations
before income taxes
Provision
(credit) for income taxes
Income (loss) from continuing
operations
Discontinued
operations:
Loss from operations
Estimated
gain (loss) on disposition
Income (loss) before extraordinary
item
Extraordinary
item--tax benefit
of utilization
of net operating
loss carryforward
Net income (loss)
The accompanying
notes are an integral

EARNINGS

Sep 29 1990
22,884,000
1,133,000
24,017,000

32,769,000
978,000
11,404,000
923,000
230,000

26,798,000
1,546,000
12,146,000
1,175,000
12,465,000

82,000
46,386,000

408,000
54,538,00

1,706,000
36,130,000

6,249,000
2,150,000

-19,663,000
-1,736,000

-12,113,000
-5,000,000

4,099,000

-17,927,000

-7,113,000

NA -11,648,000
1,696,000 -12,510,000
5,795,000

-42,085,000

20,434,000
1,948,000
10,940,000
1,102,000
NA

-7,640,000
NA
-14,753,000

2,150,000
NA
NA
7,945,000 -42,085,000
-14,753,000
part of these statements.

FINANCIAL
FOOTNOTES:
(SOURCE 10-K)
NOTES TO FINANCIAL
STATEMENTS
The Company operates
in one business segment, the manufacture
and
distribution
of generic pharmaceuticals.
Products are marketed principally
in
oral solid (tablet and capsule) form.
Product Development:-Product
development
expenses consist primarily
of
research and development
costs. All such costs are expensed as incurred.
MANAGEMENT
DISCUSSION:
MANAGEMENT'S
DISCUSSION
AND ANALYSIS OF FINANCIAL
CONDITION
AND RESULTS OF
OPERATIONS
Operating
Expenses
Product Development
Product development
costs for the
year ended October 3, 1992 of $978,000 decreased or 37% from fiscal 1991 costs.
The decrease was due to management's
decision during the prior year to suspend
all product development
efforts relating to the oral liquid and topical product
lines, as well as to curtail efforts relating to the oral solid product line.
Management
has decided to revitalize
its product development
efforts in fiscal
1993 relating to the oral solid product line, including hiring additional
personnel,
purchasing
raw material and contracting
with outside laboratories
to
conduct biostudies
and, accordingly,
expects related costs to increase
substantially
from current levels.
In addition,
the Company is actively
pursuing alternatives
to supplement
its internal product development
efforts,
such as joint ventures,
licensing
agreements
and the reintroduction
of
additional
products
from the distribution
moratorium
(see "Results of
Operations--Sales"
above).
There can be no assurance
that these efforts will
be successful.
FDA has advised Par that FDA will not review new product applications
submitted by Par, nor will Par be eligible to receive new drug application
approvals, before the conclusion of the validity assessment process (see "Notes
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to Financial Statements--Contingencies
and Other Matters--Validity
Assessments
by FDA").
The Company has been taking, and intends to continue to take, any
necessary
steps to conclude the validity assessment
process. Management
is
unable to predict the impact that the validity assessment
process will have on
future results of operations.
Product development
costs in fiscal 1991 of $1,546,000 decreased $402,000 or
21% from $1,948,000
in the fiscal 1990 year.
Such decrease was due to
management's
decision during fiscal 1991 to suspend all product development
efforts relating to the oral liquid and topical products
lines, as well as
curtail efforts relating to the oral solid product line.
Although the major portion of the regulatory
audits being conducted
by the
Company's outside consultant
is complete, the Company is unable to predict the
length of time that it will take for the balance of the regulatory
reviews and
audits to be concluded,
nor is it able to predict the extent or magnitude
of
any additional
corrective
actions that may be necessary due to review or audit
findings or the results of FDA's validity assessments
(see "Notes to Financial
Statements--Contingencies
and Other Matters--Validity
Assessments
by FDA").
Accordingly,
it is possible that the Company will incur additional
costs to be
reported under this item, and such costs may be material.
STAAR

SURGICAL

FINANCIAL
NA;

CO

STATEMENT

Income

TEXT:

Statement

Data

FINANCIAL
FOOTNOTES:
NA; Data provided only

should

for NYSE,

be available

AMEX

by 07/26/93.

and Fortune

1,00 companies.

MANAGEMENT
DISCUSSION:
ITEM 7. MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Overview
Since its inception in 1992, the Company has directed its efforts
to providing products,
systems, procedures,
and technology
that restore vision
through small incision cataract surgery, save vision through glaucoma surgery,
and now provide better vision through implantable
contact lenses.
The new management
team ef fected a turn-around
in the Company
by:
1)
obtaining pre-market approval from the FDA in September 1991 for the unrestricted
sale in the United
States
of the Company's
ELASTIC(tm)
and ELASTIMIDE(tm)
foldable IOL's, 2) obtaining approvals to market the same products in most other
countries,
3) resolving
and settling
significantly
all of the Company's
substantial
and costly
litigation,
4) licensing
the Company's
technology
to
generate
approximately
$11.6 million
in non-dilutive
capital to eliminate
the
Company's
capital
deficiency
and to provide
cash flow for various
corporate
purposes
until such time as the Company
generates
a profit,
and 5) raising
capital from private placements of the Company's securities,
also for the purpose
of eliminating
the Company's
capital
deficiency
and to provide cash flow for various corporate
purposes pending
profitability.
This significant
sales growth resulted primarily from increased sales of the
Company's
foldable IOLs which were approved by the FDA in September
1991 for
marketing
and sales in the United States. The sales growth when considering
only foldable IOL's was over 300%.
Research
and Development
Research and Development
costs nominally
increased
13.4% over the 1991 level.
The Company's
R&D efforts have been
focused on reducing the cost to manufacture
current products;
making current
products easier to use, making current products
less invasive during surgery,
and developing
new products
for better vision care.
The Company has reduced
its costs of manufacturing,
and has designed and introduced
products that are
easier to use than any other competitive
products
in the marketplace.
As a
direct result of these R&D efforts, the Company has recently announced two new
lens products,
the TORIC(tm)
foldable IOL used for patients with astigmatism,
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and the implantable contract lens (ICL) which is aimed at the general vision
care marketplace.
All of these technological advancements should enhance the
future sales growth of the Company. The Company continues to demonstrate its
technological leadership in vision care marketplace.
Research and Development
Research and development expenses
approximately 8.3% for 1991 compared to 1990. The decrease was decreased by
to the fact that most of the research required for FDA approval primarily due
of the
ELASTIC(tm) and ELASTIMIDE(tm) IOLs was completed in 1990.
UNIVERSITY

PATENTS

IRC

UNIVERSITY
PATENTS, INC. AND SUBSIDIARIES
Consolidated
Statements
of Operations
For the years ended July 31, 1992, 1991 and

Revenues:
Retained royalties
Computer-based
education

services

General and administrative
expenses,
including
costs of technology
management
business of which
$60,000, $89,000 and $200,000
were paid to related parties
Costs of computer-based
education
services,
including
$92,000,
$143,000 and $120,000 paid to
related parties
Reversal of accrued rent
liability
Operating
loss
Gain on issuance of shares by
subsidiary
Net gain on sale of investments
Interest income
Interest expense
Losses related to equity method
affiliates
Loss from continuing
operations
before income taxes and minority
interest
Provision
(benefit) for income taxes
Loss from continuing
operations
before minority
interest
Minority
interest in losses of
consolidated
subsidiary
Loss from continuing
operations
Discontinued
operations:
Gain (loss) on disposal
Net loss
See accompanying
notes

1990

1992

1991

1990

504,143
2,030,291
2,534,434

450,578
1,193,643
1,644,221

423,297
621,344
1,044,641

1,103,717

1,214,968

1,281,255

2,577,298

1,912,340

1,518,001

NA
3,681,015
-1,146,581

-960,400
2,166,908
-522,687

NA
2,799,256
-1,754,615

44,018
28,037
85,313
-73,329
-503,882

NA
NA
249,852
-18,003
-1,303,155

NA
17,194
253,520
-597
-886,686

-1,566,424
-60,000

-1,593,993
18,715

-2,371,184
14,457

-1,506,424

-1,612,708

-2,385,641

339,409
-1,167,015

316,504
-1,296,204

273,782
-2,111,859

NA
-1,296,204

-491,079
-2,602,938

180,504
-986,511

FINANCIAL
FOOTNOTES:
Income and Expenses-Expenditures
made in connection
with evaluating
the
marketability
of inventions,
pursuing patent applications,
licensing patents
and patent litigation
are charged to operations
as incurred.
PRESIDENT'S
LETTER:
FROM ANNUAL REPORT

TO SHAREHOLDERS)
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Dear Shareholder:
Subsequent to the end of fiscal 1992, University Patents made a major
strategic move. It returned to the university-based technology transfer
business and now actively seeks new university clients whose technologies it
will attempt to commercialize.
This comes at a time when corporate research
and development is on the wane and universities continue to maintain their
preeminence as America's greatest source of basic research.
The acquisition of 80% of Lehigh University's technology unit,
Competitive Technologies, Inc. (CTI) in October, 1992, was the culmination of
a strong corporate inclination to return to what University Patents does best
evaluate, license and commercialize inventions arising fro university
research. When UPI sold its technology transfer business in 1988, the
environment was much different -- the entrepreneurial spirit was sweeping
campus administrations and industry was investing heavily in R&D. But that
climate has now changed, leading UPI to believe that the time is right to
reenter the field, but with a different set of rules and priorities.
UPI's previous modus operandi was to work with universities on a totally
contingent basis, with UPI bearing all the expenses of evaluating, patenting
technologies and searching for licensees to further develop the technologies
and bring them to market. With the purchase of CTI, UPI has created a
partnership with Lehigh University for the management of the university's new
inventions. CTI has a five-year contract (subject to conditions) under which
the university pays an annual fee to CTI and provides facilities and
resources to help defray some of the costs associated with the
commercialization process. At the same time, CTI retains a healthy interest
in the successful conclusion of licenses obtained on those technologies. The
Lehigh-UPI partnership creates an environment that reduces operating costs
and risks for both parties. UPI plans to use the CTI partnership as a model
for contracts it hopes to strike with other universities and Federal
agencies/labs with technology to offer. CTI has also brought to UPI a number
of government relationships with groups such as the National Science
Foundation and the U.S. Department of Defense under revenue-producing tech
transfer and collaborative R&D management contracts.

An important UPI technology - the anti-photoaging product Retin-A - is
now before the Food and Drug Administration.
Once FDA approval is granted to
Johnson & Johnson, its producer, and sales volume begins to build, we except
that this product will generate significant royalty income for our Company.
VISX IRC
VISX, Incorporated
and Subsidiaries
ONSOLIDATED
STATEMENTS
OF OPERATIONS
For the years ended December
31, 1992,
(In thousands,
except per share data)

1991

Revenues:
Product sales
Product sales to Alcon, a related
party
Development
revenues
Service and other revenues
Total revenues
Costs and Expenses:
Cost of sales
Marketing,
general and administrative
Research,
development
and regulatory
Purchased
research and development
Total costs and expenses
Loss from Operations
Other Income (Expense):
Interest expense
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and 1990

1992

1991

1990

9,368

11,182

5,977

9,566
24
1,327
20,285

1,678
61
250
13,171

NA
572
72
6,621

12,551
6,846
5,445
6,017
30,859
-10,574

8,285
4,624
2,664
NA
15,573
-2,402

4,126
6,034
4,472
NA
14,632
-8,011

-20

-4

-12

would require treatment
achieve optimum visual
lenses.

for both nearsightedness
acuity and to eliminate

and astigmatism
in order
the need for corrective

to

MANAGEMENT
DISCUSSION:
MANAGEMENT'S
DISCUSSION
AND ANALYSIS OF FINANCIAL
CONDITION
AND RESULTS OF
OPERATIONS
Research,
development
and regulatory
expenses
increased
$2,781,000,
or
104%, in 1992 compared to 1991.
This increase reflects the Company's continued
investment
in research,
development
and regulatory
personnel,
increases
in
material
costs, increases
in regulatory
expenses associated
with the FDA
studies and the addition of Questek's
research and development
organization.
Research, development
and regulatory
expenses decreased
$1,808,000,
or 40%, in
1991, compared to the prior year.
This decrease reflects reductions
in
research,
development
and regulatory
personnel
consultants
and product
development
material expenses resulting
from the consolidation
of operations
after the Merger.
K V PHARMACEUTICALS
K V PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Years Ended March 31, 1992, 1991, and

1992

Revenues:
Net Sales
Investment
Income
Total Revenues
Costs and Expenses:
Manufacturing
Costs
Research and development
Selling and administrative
Interest expense
Total Costs and Expenses
Loss before income taxes
Provision
for income taxes
Net Loss
MANAGEMENTS

1990
1991

1990

41,368,435
650,171
42,018,606

34,457,148
663,195
35,120,343

30,147,069
1,440,791
31,547,860

27,808,368
4,880,180
8,468,429
1,009,785
42,166,762
-148,156
NA
-148,156

23,959,032
4,218,469
7,036,148
1,329,255
36,543,904
-1,423,561
NA
-1,423,561

22,152,713
3,926,743
5,617,371
900,288
32,597,115
-1,049,255
NA
-1,049,255

DISCUSSION

During fiscal 1992, research and development
costs increased to $4,880,180,
an increase of 16% over the prior year.
As a percent of revenue, these costs
remained
at 12%.
Research
and development
expenses were $4,219,469
in fiscal
1991 and $3,926,743
in fiscal 1990.
These costs are linked directly
to the
expansion
of
the
Company's
drug
delivery
technologies
and
new
product
development.
The Company expects these expenditures
to continue at a relatively
high level related to proprietary
new products.
Compared to a new drug entity, which is a drug molecule that has never been
approved by the FDA or commercially
marketed,
an Improved Drug Entity(TM)
is a
patented
or off-parent
drug (already approved by the FDA for marketing
in its
original form) which has been converted by a K V drug delivery system technology
to have differentiated
and improved benefits.
The Company expects to continue a relatively high level of expenditures
and
investment for research, clinical, and regulatory efforts relating to development
and commercialization
of proprietary
new and Improved Drug Entities(TM)
and their
approval for marketing.
Delays in FDA approvals have been experienced
industrywide by pharmaceutical
companies
in general and there can be no assurance
such
delays will not continue.
A.
A.

L.
L.

LABORATORIES,
LABORATORIES,

INC.
INC.

AND SUBSIDIARIES
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l

CONSOLIDATED
STATEMENT OF INCOME
(In thousands)
Years Ended December 31
Total revenue
Cost of sales
Gross profit
Selling, general and administrative
expenses
Operating
income
Interest expense
Other income (expense), net
Income from continuing
operations
Provision
for income taxes
Income from continuing
operations
Income from discontinued
operations
Net Income
MANAGEMENTS

1992
295,112
116,947
128,165

1991
257,129
144,283
112,846

1990
241,375
131,121
110,254

99,671
28,494
-10,134
-785
17,575
6,208
11,367
4,809
16,176

99,156
13,690
-12,098
174
1,766
1,187
579
4,502
5,081

78,063
32,191
-11,652
709
21,248
8,025
13,223
883
14,106

DISCUSSION

Reasons for the decision included the delays experience
by the Company in
obtaining
drug approvals
by the FDA, while maintaining
an increased
level of
expenses
related
to personnel,
research,
product
development,
and clinical
testing necessary
to support regulatory
submissions
and approvals.
The development,
manufacturing
and marketing of the Company's products are
subject to regulation which includes inspections
and controls over manufacturing
practices
and procedures,
requires approval to market products,
and can result
in the recall of products and suspension of production.
In the United States the
Food
and Drug
Administration(FDA),
has imposed
increasingly
comprehensive
oversight
and more stringent
regulatory
requirements
on the pharmaceutical
industry,
with the result of substantially
increasing
the cost of regulatory
compliance
incurred in the production
and marketing
of pharmaceutical
products.
Operating
expenses
in 1991 included costs for regulatory
compliance.
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